GTC Biotherapeutics (fka GTCB)

[go seek]

"It seems a number of posters on this site have focused in on the upcoming decision of the FDA to approve Atryn as a sentinel event for GTC and one which would cause an immediate and long term dramatic rise in the PPS."

Are you prepared to predict the PPS of GTC after ATryn approval? A difficult - impossible task... we may be surprised by the upside (and we may be disappointed).

We agree; the AD indications, particularly DIC are the potential homeruns as per ATryn... but GTC must get to the plate first with the HD approval. That action will help open doors. i.e. If ATryn fails in the HD indication we won't be considering it in the US for DIC, CABG, et al.

We should not discount any clinical progress made by the company (and I know you are not) the FDA approval of ATryn, an ATryn partnership for Japan, a partnership for CD137 or partnerships for the FoB's, etc.

Best wishes JL...